Entera Bio Ltd.

ENTX Healthcare Biotechnology

Entera Bio Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42,000.00, down 76.8% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS fell 133.3% and free cash flow fell 108.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.51 0.14 −5.28%
Market cap
$460.7M
P/E
0.0×
Fwd P/E
−3.5×
Dividend yield
—
F-score
n/a
Altman Z
6.22
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Total current assets
5.43 12.42 12.47 15.64 9.11 25.33 12.85 11.26 8.97 15.30
Total non-current assets
— 0.86 0.88 1.07 0.61 0.66 0.28 0.51 0.42 0.70
Total Assets
6.29 13.28 13.34 16.70 9.72 25.99 13.13 11.77 9.39 15.99
Total current liabilities
10.54 2.02 3.16 4.59 1.84 3.16 1.34 1.09 1.18 2.20
Total non-current liabilities
— 42.82 0.07 0.19 0.37 0.26 0.03 0.29 0.13 0.69
Total liabilities
31.53 44.84 3.23 4.78 2.21 3.42 1.37 1.38 1.31 2.89
Common Equity (Total)
(25.25) (31.56) 10.12 11.92 7.51 22.57 11.75 10.39 8.08 13.10
Shareholders Equity (Total)
(25.25) (31.56) 10.12 11.92 7.51 22.57 11.75 10.39 8.08 13.10
Total Debt
25.75 3.89 — 0.12 0.24 0.12 0.09 — — —

Show all line items

In millions of $ except per-share values · columns are period end dates